Introduction
Limited evidence currently exists to guide practice regarding folate intake or supplementation during methotrexate (MTX) treatment in oncology settings. Although the nutrient folate plays a vital role in hematopoiesis and cell repair processes following myeloablative treatment regimens, concerns that folate may impair MTX effectiveness or selectively rescue cancer cells have led some clinicians to restrict supplemental folic acid during MTX administration. 1, 2 An unusual nationwide intravenous multivitamin shortage in the United States from late 1996 through the end of 1998 allowed a unique opportunity to evaluate the effect of variation in supplemental folic acid intake on MTX toxicity and treatment effectiveness following hematopoietic cell transplantation (HCT). Methotrexate is commonly used as an immunosuppressive agent for prophylaxis against acute graft-versus-host disease (GVHD) immediately following HCT, and toxicities include mucositis and myelosuppression. [3] [4] [5] The majority of HCT patients receive parenteral nutrition as their primary source of nutrients, including folate, during the early post-transplant period. During the nationwide intravenous multivitamin shortage, recommendations from the FDA, the Centers for Disease Control and Prevention, and the American Society for Parenteral and Enteral Nutrition were to limit the frequency of intravenous multivitamin infusions to three times per week, and to use oral supplements for patients able to absorb at least 50% of their nutrients enterally. 6 In addition to these guidelines, our center added 1 mg folic acid daily as an individual supplement to each patient's parenteral nutrition solution. Thus, patients were receiving as much as 1400 mg folic acid/day (usual amount was 400 mg folic acid/day) during both parenteral nutrition support and oral multivitamin supplements, effectively resulting in greater folic acid supplementation during this period of vitamin 'shortage'.
Folic acid, the synthetic monoglutamic form of folate used in vitamin supplements and fortified foods, must be reduced to tetrahydrofolate by the enzyme dihydrofolate reductase in order to be metabolically active within the cell and act as a methyl group donor for nucleotide synthesis. As most of the antifolate agents specifically block the action of dihydrofolate reductase, we hypothesized that folic acid is not likely to be metabolically active during antifolate treatment and should not affect treatmentrelated toxicity or outcomes.
Materials and methods
Study design and patient population Subjects in this retrospective cohort study were patients receiving allogeneic HCT at the Fred Hutchinson Cancer Research Center (FHCRC) between 1992 and 2002 who: (1) had a diagnosis of CML in chronic or accelerated phase before transplant, (2) were 18 years of age or older at the time of transplant and (3) received myeloablative conditioning regimens with either cyclophosphamide/total body irradiation (CyTBI) or busulfan/cyclophosphamide (BuCy), as previously described. 7, 8 None of the patients received marrow or peripheral blood stem cell infusions that were T-cell depleted. Additional eligibility criteria restricted the study cohort to patients who received cyclosporine and all four scheduled doses of MTX (15 mg/m 2 on day 1; 10 mg/m 2 on days 3, 6 and 11 post transplant) for GVHD prophylaxis following previously described protocols, 9 and did not require leucovorin rescue. This study was approved by the FHCRC Institutional Review Board, and all patients provided informed consent to use medical records for research.
Data collection
Medical records and patient databases were used to abstract study data for each study participant. Data collected included height, weight, body surface area, body mass index (kg/m 2 ), age, sex, race, time from diagnosis to transplant, conditioning regimen, source of hematopoietic progenitor cells (bone marrow vs peripheral blood), average busulfan concentration at steady state, donor relationship, donor sex, date of HCT, number of MTX doses and total dose received post transplant and leucovorin administration for rescue from MTX toxicity.
Data on folic acid intake from parenteral solutions and oral multivitamin supplements were abstracted from the medication administration records for days 0-18 post transplant. This time frame was chosen because most patients were hospitalized for this period of time, and medication administration records were available for documentation of folic acid intake. Furthermore, patients typically begin to engraft 10 and oral mucositis begins to resolve 4, 11 around day 18 following full myeloablative treatment regimens.
To verify reproducibility of chart abstraction data, 13 charts were selected randomly and re-abstracted. Complete agreement between the two abstractions was confirmed.
Toxicity data Severity of oral mucositis and days to granulocyte and platelet engraftment were used as indicators of MTX toxicity. Oral mucositis was measured using the oral mucositis index (OMI), which assesses clinically evident oral mucosal changes (atrophy, erythema, ulceration, pseudomembranous ulcerations and edematous changes) and consists of 34 items each scaled from 0 to 3 (normal to severe). 12 Each HCT patient at the FHCRC is examined for oral mucositis every 2-3 days during the early posttransplant period by a trained examiner. Results are recorded on a standardized machine-readable form, from which the OMI is computed. Oral mucositis following HCT is generally noted to peak between days 7 and 11, and resolve by days 18-21 post transplant. 4, 12 Therefore, outcomes identified for analyses were mean OMI days 6-12 (patients with at least two assessments during this period) and mean OMI days 1-18 (patients with at least four assessments during this period). The number of days post transplantation to reach 500 granulocytes/ml and 20 000 platelets/ml were obtained from the patient database.
Outcome data Data on acute GVHD, relapse and survival were collected from the center's patient database. The FHCRC LongTerm Follow-Up program maintains contact with patients and their referring physicians after discharge from the center, and contributes information on relapse and death to the center's patient database. Relapse was defined by cytogenetic (X5 metaphases positive for the Philadelphia chromosome at any point in time or the presence of any Philadelphia chromosome on two successive cytogenetic evaluations at least 6 months apart 13 ) or hematologic criteria. Relapse and survival data were locked for analysis on July 11, 2005.
Statistical analysis
The data were stratified by average daily supplemental folic acid intake, between days 0 and 18 post transplant, into those receiving less than, equal to or more than the USrecommended dietary intake of 400 mg/day.
14 Multiple linear regression models were used to determine the geometric mean OMI scores, time to engraftment (platelets and granulocytes) and days to developing acute GVHD (among those who developed acute GVHD) for each of the supplemental folic acid intake categories, adjusting for age, year of transplant, conditioning regimen and donor relationship (related vs unrelated). Pairwise comparisons and trend tests were used to test for differences between the group geometric means.
Multivariable logistic regression analyses were used to assess the relationship between supplemental folic acid intake and risk of detectable acute GVHD. Multivariable Cox regression analyses were used to assess the relationship between supplemental folic acid intake and risk of relapse and survival. Individuals with an average supplemental folic acid intake of 400 mg/day were used as the reference group for both the logistic and Cox regression analyses. Potential confounding factors (including year of transplant, stage of CML at time of transplant, conditioning regimen, donor relationship, age and sex) were selected for inclusion in the various models if they had either been previously shown to be modulators of the given outcome [15] [16] [17] or altered the regression coefficients of supplemental folic acid intake by at least 10%. Source of hematopoietic progenitor cells and time from diagnosis to transplant were considered as potential confounding factors, but did not significantly alter the means or regression coefficients, and thus, were not included in the models. Analyses were performed using SAS version 8.2 (SAS Institute Inc., Cary, NC, USA).
Results
A total of 311 patients met eligibility criteria for the study. Characteristics of the study population are described in Table 1 . Nearly all patients (n ¼ 302, 97%) received parenteral nutrition as their primary source of nutrients (more than half of their daily caloric intake) during the study period. Inclusion of patients (n ¼ 9) who did not require parenteral nutrition support did not alter the overall trends in the observed associations.
Average supplemental folic acid intake between days 0 and 18 post transplant varied from 0 to 1400 mg/day, with a mean of 567 mg/day. Most patients (n ¼ 166, 58%) averaged 400 mg/day, with 14% (n ¼ 57) receiving less than 400 mg/ day and 28% (n ¼ 88) receiving more than 400 mg/day on average. Forty-seven individuals (15%) did not receive any folic acid supplementation between days 0 and 18 post transplantation (Table 1) .
No statistically significant differences in mean OMI scores, time to engraftment or days to acute GVHD were observed when comparing patients taking, on average, o400 (14%), 400 (58%) or 4400 mg (28%) supplemental folic acid per day (Table 2 ). Compared with individuals receiving an average of 400 mg folic acid per day (reference group), no significant variation in risk of acute GVHD, relapse or survival was observed for those receiving more than or less than 400 mg folic acid per day. No clear trends were observed for the relationship between increasing folic acid intake and OMI scores or days to 500 granulocytes/ml. Although not statistically significant, a trend toward delayed platelet recovery (days to 20 000 platelets) was observed for increasing folic acid intake (P-trend ¼ 0.14) ( Table 2) .
Discussion
To our knowledge, this is the first study to evaluate the effects of early post-transplant folic acid supplementation on toxicity and outcomes in the HCT population. We have previously reported that pre-transplant multivitamin supplement use (before MTX administration) was associated with lower mean OMI scores in this cohort; 16 however, detailed information on duration of supplement use or actual composition of the individual supplement was not available for our previous analysis. The current study focused on the effect of folic acid supplementation during MTX treatment, and utilized medication administration records to compile actual folic acid intake data over a specific post-transplant period (days 0-18 post transplant). Our findings are in keeping with two studies in mice 18, 19 and an observational study of children receiving high-dose MTX for acute lymphocytic leukemia, 1 which suggest that folic acid supplementation during MTX therapy does not appear to negate treatment effects and may, in fact, be beneficial. Mead and colleagues 18 found that mice given folic acid (25 mg/kg/day) 1 h before or at the same time as the MTX (0.75 or 1.5 mg/kg) had significantly longer median survival times than mice given 20 mg/kg/day folinic acid (leucovorin, 5-formyltetrahydrofolate, a downstream product of the 19 found that mice given a large dose of folic acid (62.5 mg/kg) at the same time as MTX (8.7 mg/kg) had a statistically significant increase in median survival time compared with mice given MTX without folic acid and mice given folic acid either 12 or 24 h before MTX administration. The authors proposed several hypotheses that might explain their findings. The first was that the folic acid becomes trapped within the cell as dihydrofolate, which later is reduced to THF once MTX has been cleared and dihydrofolate reductase activity is regenerated, thus sparing marginally viable normal tissues that otherwise would have experienced significant toxicity. Their second hypothesis was that folic acid and MTX compete for renal excretion, and folic acid may retard elimination of MTX, thus increasing the amount of time tumor cells are exposed to the drug. Although MTX is given at much lower doses for its immunosuppressive properties rather than its antineoplastic properties in the HCT setting, if this second hypothesis were true, we might have expected to see some evidence of a decreased risk of relapse among individuals who received greater amounts of supplemental folic acid; this was not seen.
A cross-sectional observational study of children with acute lymphocytic leukemia receiving maintenance chemotherapy with high-dose MTX (20 mg/m 2 per week) and 6-mercaptopurine 1 is the only human study to evaluate the effect of folic acid supplementation before and continuing through MTX treatment. At 8 weeks after beginning therapy, slightly more than half of the patients (54%, 25 of 46) had been taking folic acid supplements (75-200 mg/ day) for at least 3 months, whereas 46% (21 of 46) had not received any supplementation. The researchers found that none of the children were folate deficient based on erythrocyte folate levels, and suggested that folic acid should not be given during MTX treatment. However, because erythrocytes have a half-life of approximately 120 days, erythrocyte folate levels at 8 weeks after beginning treatment would reflect both pre-treatment folate status and folate status after MTX exposure. They also reported no difference in erythrocyte MTX levels between patient who received folic acid supplements and those who did not, suggesting that folic acid supplementation did not compete with MTX for uptake into cells. The study did not evaluate the effect of folic acid supplementation on treatment outcomes, and dietary folate intake was not considered as a potential effect modifier.
Studies on the effect of oral folic acid supplementation during MTX treatment in the rheumatoid arthritis (RA) population, where MTX doses are more comparable to those given following HCT, have generally found improved drug tolerance and minimal interference with drug effectiveness. 20, 21 In a meta-analysis, Ortiz et al. 22 found a statistically significant reduction in mucosal and gastrointestinal side effects for RA patients receiving MTX with folic acid supplementation (odds ratio ¼ 0.21, 95% confidence interval: 0.1-0.4) compared with individuals who did not receive supplementation. Patients receiving folinic acid supplementation reported less toxicity, but also reported a more modest improvement in joint tenderness. Current recommendations from the European rheumatology community call for prescription of 5 mg folic acid per day orally in patients who are taking MTX for the treatment of RA 23 or evaluation of dietary folate intake and supplementation as needed. 24 The FDA recently amended its requirements for adult parenteral multivitamin products, increasing the requirement for folic acid from 400 to 600 mg per unit dose. 25 Our study suggests that this increase in standard parenteral folic acid supplementation will have no detrimental effects on the HCT patient population.
A limitation of this study is that the multivitamin shortage leading to the variation in folic acid intake occurred for all patients undergoing HCT during a specified time period. The time dependency of this variation in intake might have masked the effects of other unidentified, time-dependent factors contributing to treatment-related toxicity and outcome such as improvements in supportive care, although this would be an odd coincidence.
Another limitation is the lack of accurate, quantitative data on pre-transplant supplemental folic acid intake, dietary folate intake throughout the pre-and posttransplant period or measurements of pre-transplant folate status as indicated by erythrocyte folate levels or plasma homocysteine levels. It is likely that pre-transplant folate intake and/or folate status has a greater effect on MTX response during the early post-transplant period, as suggested by our previous report. 16 Protocols for more recently developed antifolate drugs, including pemetrexed [26] [27] [28] and lometrexol, 29 call for optimizing the patient's folate status with folic acid supplementation before treatment and between treatment cycles in attempts to minimize treatment-related toxicity in normal tissues.
In summary, supplementing folic acid up to 1400 mg/day did not mitigate MTX toxicity or treatment outcome in this HCT population. Prospective studies, which include assessment of pre-transplant folate status, are needed to confirm these findings within the HCT population, as well as other oncology patient populations, especially those receiving high-dose MTX.
